Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

PEPI in Perspective

PEPI in Perspective Estrogen is good for a woman's heart. While generally accepted when the estrogen is produced naturally, this theory has been a matter of great controversy when the estrogen is administered "artificially" in hormone replacement therapy (HRT) for women during and after menopause. After a half century of conflicting data, we can affirm with growing confidence that, at the very least, estrogen reduces key cardiovascular risk factors in women at a time when they become especially vulnerable to heart disease, namely, after 50 years of age. See also p 199. In this issue of The Journal, the Postmenopausal Estrogen/Progestin Interventions (PEPI) investigators report on one aspect of the many findings that we can expect to learn over the next few years from their important National Institutes of Health (NIH)-supported multicenter efforts.1 Their report focuses on the effect of HRT, given in four different formulations, compared with short-term use of placebo http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png JAMA American Medical Association

PEPI in Perspective

JAMA , Volume 273 (3) – Jan 18, 1995

Loading next page...
 
/lp/american-medical-association/pepi-in-perspective-jacgKegHJJ

References (6)

Publisher
American Medical Association
Copyright
Copyright © 1995 American Medical Association. All Rights Reserved. Applicable FARS/DFARS Restrictions Apply to Government Use.
ISSN
0098-7484
eISSN
1538-3598
DOI
10.1001/jama.1995.03520270074035
Publisher site
See Article on Publisher Site

Abstract

Estrogen is good for a woman's heart. While generally accepted when the estrogen is produced naturally, this theory has been a matter of great controversy when the estrogen is administered "artificially" in hormone replacement therapy (HRT) for women during and after menopause. After a half century of conflicting data, we can affirm with growing confidence that, at the very least, estrogen reduces key cardiovascular risk factors in women at a time when they become especially vulnerable to heart disease, namely, after 50 years of age. See also p 199. In this issue of The Journal, the Postmenopausal Estrogen/Progestin Interventions (PEPI) investigators report on one aspect of the many findings that we can expect to learn over the next few years from their important National Institutes of Health (NIH)-supported multicenter efforts.1 Their report focuses on the effect of HRT, given in four different formulations, compared with short-term use of placebo

Journal

JAMAAmerican Medical Association

Published: Jan 18, 1995

There are no references for this article.